Author
Listed:
- Felicity Newell
(QIMR Berghofer Medical Research Institute)
- Yan Kong
(Peking University Cancer Hospital & Institute)
- James S. Wilmott
(The University of Sydney
The University of Sydney)
- Peter A. Johansson
(QIMR Berghofer Medical Research Institute)
- Peter M. Ferguson
(The University of Sydney
The University of Sydney)
- Chuanliang Cui
(Peking University Cancer Hospital & Institute)
- Zhongwu Li
(Peking University Cancer Hospital & Institute)
- Stephen H. Kazakoff
(QIMR Berghofer Medical Research Institute)
- Hazel Burke
(The University of Sydney)
- Tristan J. Dodds
(The University of Sydney
The University of Sydney)
- Ann-Marie Patch
(QIMR Berghofer Medical Research Institute)
- Katia Nones
(QIMR Berghofer Medical Research Institute)
- Varsha Tembe
(The University of Sydney)
- Ping Shang
(The University of Sydney)
- Louise van der Weyden
(Wellcome Trust Sanger Institute, Hinxton)
- Kim Wong
(Wellcome Trust Sanger Institute, Hinxton)
- Oliver Holmes
(QIMR Berghofer Medical Research Institute)
- Serigne Lo
(The University of Sydney
The University of Sydney)
- Conrad Leonard
(QIMR Berghofer Medical Research Institute)
- Scott Wood
(QIMR Berghofer Medical Research Institute)
- Qinying Xu
(QIMR Berghofer Medical Research Institute)
- Robert V. Rawson
(The University of Sydney
Royal Prince Alfred Hospital)
- Pamela Mukhopadhyay
(QIMR Berghofer Medical Research Institute)
- Reinhard Dummer
(University Hospital Zürich, University of Zurich)
- Mitchell P. Levesque
(University Hospital Zürich, University of Zurich)
- Göran Jönsson
(Lund University)
- Xuan Wang
(Peking University Cancer Hospital & Institute)
- Iwei Yeh
(University of California, San Francisco (UCSF))
- Hong Wu
(Fox Chase Cancer Center)
- Nancy Joseph
(University of California)
- Boris C. Bastian
(University of California, San Francisco (UCSF))
- Georgina V. Long
(The University of Sydney
The University of Sydney
Royal North Shore and Mater Hospitals)
- Andrew J. Spillane
(The University of Sydney
The University of Sydney)
- Kerwin F. Shannon
(The University of Sydney
The University of Sydney)
- John F. Thompson
(The University of Sydney
The University of Sydney
Royal Prince Alfred Hospital)
- Robyn P. M. Saw
(The University of Sydney
The University of Sydney)
- David J. Adams
(Wellcome Trust Sanger Institute, Hinxton)
- Lu Si
(Peking University Cancer Hospital & Institute)
- John V. Pearson
(QIMR Berghofer Medical Research Institute)
- Nicholas K. Hayward
(QIMR Berghofer Medical Research Institute)
- Nicola Waddell
(QIMR Berghofer Medical Research Institute)
- Graham J. Mann
(The University of Sydney
The University of Sydney)
- Jun Guo
(Peking University Cancer Hospital & Institute)
- Richard A. Scolyer
(The University of Sydney
The University of Sydney
Royal Prince Alfred Hospital)
Abstract
Knowledge of key drivers and therapeutic targets in mucosal melanoma is limited due to the paucity of comprehensive mutation data on this rare tumor type. To better understand the genomic landscape of mucosal melanoma, here we describe whole genome sequencing analysis of 67 tumors and validation of driver gene mutations by exome sequencing of 45 tumors. Tumors have a low point mutation burden and high numbers of structural variants, including recurrent structural rearrangements targeting TERT, CDK4 and MDM2. Significantly mutated genes are NRAS, BRAF, NF1, KIT, SF3B1, TP53, SPRED1, ATRX, HLA-A and CHD8. SF3B1 mutations occur more commonly in female genital and anorectal melanomas and CTNNB1 mutations implicate a role for WNT signaling defects in the genesis of some mucosal melanomas. TERT aberrations and ATRX mutations are associated with alterations in telomere length. Mutation profiles of the majority of mucosal melanomas suggest potential susceptibility to CDK4/6 and/or MEK inhibitors.
Suggested Citation
Felicity Newell & Yan Kong & James S. Wilmott & Peter A. Johansson & Peter M. Ferguson & Chuanliang Cui & Zhongwu Li & Stephen H. Kazakoff & Hazel Burke & Tristan J. Dodds & Ann-Marie Patch & Katia No, 2019.
"Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets,"
Nature Communications, Nature, vol. 10(1), pages 1-15, December.
Handle:
RePEc:nat:natcom:v:10:y:2019:i:1:d:10.1038_s41467-019-11107-x
DOI: 10.1038/s41467-019-11107-x
Download full text from publisher
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:10:y:2019:i:1:d:10.1038_s41467-019-11107-x. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.